[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-or-metastatic-cervical-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-or-metastatic-cervical-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,70,95,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100642190","tte-study-of-ql1706-in-recurrentmetastatic-cervical-cancer-100642190",false,"NCT07652983","TTE Study of QL1706 in Recurrent\u002FMetastatic Cervical Cancer","Real-World Effectiveness and Safety of Iparomlimab and Tuvonralimab in Recurrent or Metastatic Cervical Cancer: A Target Trial Emulation Study","Inclusion Criteria:\n\n* Participants voluntarily agree to participate in the study and provide written informed consent.\n* Age ≥18 years at the time of signing the informed consent form.\n* Histologically confirmed recurrent or metastatic cervical cancer (FIGO 2018 stage IVB), including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n* Disease progression or treatment failure following prior platinum-based chemotherapy.\n* At least one measurable target lesion according to RECIST version 1.1, as assessed by CT or MRI.\n* Estimated life expectancy of at least 3 months.\n* Considered suitable by the investigator for antitumor treatment with Iparomlimab and Tuvonralimab (QL1706), either as monotherapy or in combination with other therapies, and with a planned treatment regimen including QL1706.\n\nExclusion Criteria:\n\n* Histological subtypes including sarcoma, small-cell carcinoma with neuroendocrine differentiation, or other non-epithelial malignancies.\n* History of severe hypersensitivity reaction (Grade ≥3) to Iparomlimab and Tuvonralimab (QL1706) and\u002For any of its excipients.\n* Known additional malignancy that has progressed or required active treatment within the past 3 years.\n* Active autoimmune disease requiring systemic treatment within the past 2 years (e.g., disease-modifying agents, corticosteroids, or immunosuppressive therapy); history of non-infectious pneumonitis requiring steroid treatment, or current pneumonitis.\n* Active infection requiring systemic therapy.\n* Any other medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would make the participant unsuitable for participation in this study.","FEMALE","18 Years",{"count":19,"type":20},280,"ESTIMATED","2 Years","OBSERVATIONAL","The goal of this observational study is to evaluate the effectiveness and safety of Iparomlimab and Tuvonralimab (QL1706)-based therapy in patients with recurrent or metastatic cervical cancer who have experienced disease progression after platinum-based treatment.\n\nThe main questions it aims to answer are:\n\n* Does QL1706-based therapy improve clinical outcomes compared with investigator-selected chemotherapy in patients with recurrent or metastatic cervical cancer?\n* Does the addition of bevacizumab further improve treatment effectiveness?\n* Which patient subgroups are most likely to benefit from QL1706-based therapy? Participants receiving QL1706-based therapy or investigator-selected chemotherapy as part of routine clinical practice will be followed through real-world clinical data collection. Using a target trial emulation framework, the study will compare treatment effectiveness and safety between groups. Clinical characteristics, treatment outcomes, and adverse events will be collected for analysis. In addition, artificial intelligence-based models and multi-omics analyses will be used to identify predictive biomarkers and explore potential mechanisms of treatment response and resistance.",[25],"Recurrent or Metastatic Cervical Cancer",[27,28],"Recurrent or metastatic cervical cancer","Iparomlimab and Tuvonralimab","NOT_YET_RECRUITING","2026-06-11",{"date":32,"type":33},"2026-06-17","ACTUAL",{"date":35,"type":20},"2026-06-15",{"date":37,"type":20},"2029-12-31",{"name":39,"class":40},"Qilu Hospital of Shandong University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100634671","phase-1-ascerv-study-mrg003-combined-with-ql1706-in-recurrent-or-metastatic-cervical-cancer-100634671","NCT07542717","ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer","A Single-Arm, Multicenter, Phase II Study of MRG003 Combined With QL1706 for Second-Line or Later Treatment of Recurrent or Metastatic Cervical Cancer (ASCERV Study)","Inclusion Criteria:\n\nAge ≥18 years Histologically confirmed recurrent or metastatic cervical cancer (squamous, adenocarcinoma, or adenosquamous) Progression after ≥1 line of platinum-based therapy At least one measurable lesion per RECIST v1.1 ECOG performance status 0-1 Life expectancy ≥12 weeks Adequate organ function Recovery from prior treatment toxicities (≤ Grade 1) Agreement to use effective contraception Signed informed consent\n\nExclusion Criteria:\n\nActive malignancy within 5 years (except certain cured cancers) Active CNS metastases Significant cardiovascular disease Uncontrolled comorbidities Active hepatitis B\u002FC or uncontrolled HIV infection Interstitial lung disease or pneumonitis Prior EGFR-targeted therapy Prior T-cell co-stimulatory pathway agents Recent live vaccination Use of strong CYP3A4 inhibitors\u002Finducers Pregnancy or breastfeeding Any condition deemed unsuitable by investigator",{"count":49,"type":20},41,"INTERVENTIONAL",[52,53],"PHASE1","PHASE2","This is a single-arm, multicenter, phase II study designed to evaluate the efficacy and safety of MRG003, an anti-EGFR antibody-drug conjugate, in combination with QL1706, a PD-1\u002FCTLA-4 bispecific antibody, in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based therapy.",[25],[57,58,59,60],"Metastatic Cervical Cancer","MRG003","QL1706","Second-Line or Later Treatment","2026-04-17",{"date":63,"type":33},"2026-04-21",{"date":65,"type":20},"2026-04-10",{"date":67,"type":20},"2030-03-31",{"name":69,"class":40},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":50,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100596900","phase-2-a-phase-ii-trial-of-shr-a1811-in-her2-expressing-recurrentmetastatic-cervical-cancer-100596900","NCT07051486","A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent\u002FMetastatic Cervical Cancer","A Single-Arm, Multicenter Phase II Clinical Trial of SHR-A1811 for Injection in Patients With HER2-Expressing Recurrent or Metastatic Cervical Cancer Progressing After Standard Treatment","Inclusion Criteria:\n\n1. Voluntarily join this study, sign the informed consent, have good compliance, and can cooperate with follow-up.\n2. Female, aged 18-75 years old (including 18 and 75 years old, calculated on the day of signing the informed consent).\n3. Cervical cancer confirmed by tissue or cytological pathology.\n4. Expected survival ≥ 12 weeks.\n5. Normal function of important organs.\n6. Female subjects of fertility must have a negative serum HCG test within 7 days before the first dose of Investigational Medicinal Product (IMP), and must not be breastfeeding, and must agree to comply with contraceptive requirements from the signing of the informed consent until the last dose of the trial drug for 7 months.\n\nExclusion Criteria:\n\n1. Subjects with known untreated or active central nervous system (CNS) tumor metastases.\n2. Subjects with other malignant tumors in the past or at the same time.\n3. Subjects with clinically symptomatic, poorly controlled, or moderate or greater pleural effusion, pericardial effusion or peritoneal effusion.\n4. Subjects with a history of interstitial pneumonia\u002Finterstitial lung disease or non-infectious pneumonia requiring steroid treatment.\n5. Subjects with autoimmune, connective tissue or inflammatory diseases involving the lungs.\n6. Subjects with known lung damage caused by concurrent lung diseases.\n7. Subjects with active pulmonary tuberculosis.\n8. Subjects with poorly controlled or severe cardiovascular diseases.\n9. Subjects with arterial\u002Fvenous thrombotic events within 1 month before enrollment.\n10. Subjects who had a serious infection within 1 month before enrollment.\n11. History of immunodeficiency, including positive HIV test.","75 Years",{"count":79,"type":20},60,[53],"This study is a single-arm, multicenter Phase II clinical trial of SHR-A1811 for injection in patients with HER2-expressing recurrent or metastatic cervical cancer who have failed prior systemic therapy.",[25],"RECRUITING","2025-11-13",{"date":86,"type":33},"2025-11-17",{"date":88,"type":33},"2025-10-11",{"date":90,"type":20},"2026-08",{"name":92,"class":93},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY",2,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":102,"targetDuration":4,"studyType":50,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100582166","phase-1-shr-a1811-combination-regimen-for-the-treatment-of-recurrent-or-metastatic-cervical-cancer-100582166","NCT06859775","SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer","Open-label, Multicenter Phase Ib\u002FII Clinical Study of Injectable SHR-A1811 in Combination Regimens for the Treatment of Recurrent or Metastatic Cervical Cancer","Inclusion Criteria:\n\n1. Subjects must voluntarily join this study, sign the informed consent form, have good compliance and be able to cooperate with the follow-up.\n2. Female, aged 18-75 years old.\n3. Expected survival ≥ 12 weeks.\n4. Normal function of vital organs.\n5. Female subjects of childbearing potential must have a negative serum HCG test within 7 days prior to the first dose and must be non-lactating.\n6. Female subjects must agree to comply with contraceptive requirements from signing the informed consent form to 7 months after the last dose of the investigational drug.\n\nExclusion Criteria:\n\n1. Previous or concomitant other malignancies.\n2. Severe bone damage caused by bone metastasis from tumours.\n3. Presence of active autoimmune disease or history of autoimmune disease with possible recurrence.\n4. Those with active tuberculosis.\n5. Concomitant poorly controlled or severe cardiovascular disease.\n6. Occurrence of arteriovenous thrombotic events within 6 months prior to the first dose.\n7. Presence of gastrointestinal obstruction or presence of symptoms and signs of gastrointestinal obstruction within 6 months prior to the first dose.\n8. Subjects who have had a serious infection within 1 month before the first dose.\n9. Subjects who have a history of immunodeficiency.\n10. As judged by the investigator, there are other factors that may affect the results of the study or cause the study to be forced to terminate halfway.",{"count":103,"type":20},100,[52,53],"This study is a multicentre, open-label, dose-finding\u002Fefficacy-expanding phase Ib\u002FII clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.",[25],"2025-06-04",{"date":109,"type":33},"2025-06-06",{"date":111,"type":33},"2025-04-25",{"date":113,"type":20},"2027-01",{"name":115,"class":93},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",1,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100528027","a-prospective-real-world-study-of-cadonilimab-in-patients-with-recurrent-or-metastatic-cervical-cancer-100528027","NCT06155422","A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer","Efficacy and Safety of Cadonilimab (PD-1\u002FCTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer: a Multicenter, Prospective, Real-world Study","Inclusion Criteria:\n\n1. The subject must sign the written informed consent form (ICF) voluntarily.\n2. Aged ≥ 18years, female.\n3. Histologically or cytologically confirmed cervical cancer, ① recurrent or metastatic (FIGO IVB) cervical cancer, not amenable to curative surgery or concurrent chemoradiotherapy, no prior systemic therapy for persistent, recurrent or metastatic disease, or ② subjects have demonstrated radiologically confirmed disease progression during or after last treatment, subjects will have no more than 2 lines of systemic therapy in the recurrence or metastatic stages. neoadjuvant chemotherapy, adjuvant chemotherapy, or Chemotherapy of non-recurrent or metastatic stage chemoradiotherapy,will not be counted as a treatment line number.\n4. The histological types include squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma.\n5. At least 1 measurable lesion per RECIST v1.1, which is applicable for repeated accurate measurement.\n6. Life expectancy\\> 12 weeks.\n7. Adequate organ function.\n8. Female patients with fertility must have a urine or serum pregnancy test within 3 days before the first medication (if the urine pregnancy test result cannot be confirmed as negative, a serum pregnancy test is required, based on the serum pregnancy result), and the result is negative. If a fertile female patient has sex with an unsterilized male partner, the patient must use an acceptable contraceptive method since screening and must consent to continued use of the contraceptive method for 120 days after the last administration of the study drug; Whether to stop contraception after this time point should be discussed with the investigator\n9. Subjects must be willing and able to comply with the scheduled visits, treatment regimens, laboratory tests, and other requirements in the study.\n\nExclusion Criteria:\n\n1. Subjects had clinically significant hydronephrosis that could not be relieved by nephrostomy or urethral stenting, as determined by the investigator.\n2. Other active malignancies within 2 years prior to the first administration. Subjects with locally curable tumors that appear to be cured, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the breast, were not excluded.\n3. Have received other study drugs or study devices within 4 weeks prior to the first administration.\n4. Concurrent enrollment in another clinical study, unless it is an observational, non-interventional clinical study or a follow-up period of an interventional study. (It was defined as more than 4 weeks between the first administration of the drug in the study and the last administration of the drug in the previous clinical study or more than 5 half-lives of the drug in the study)\n5. An active infection requiring systemic therapy.\n6. Subjects with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA exceeding 1000 IU\u002F mL or active hepatitis C virus (HCV) should be excluded. Subjects with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA \\\u003C1000 IU\u002F mL), and cured hepatitis C can be enrolled. Subjects with positive HCV antibodies are eligible only if the HCV RNA test results are negative.\n7. Known history of active tuberculosis (TB),In patients suspected of having active tuberculosis, chest x-rays, sputum, and clinical signs and symptoms should be examined for exclusion.\n8. Receipt of live or attenuated vaccination within 30 days prior to the first administration, or plan to receive live or attenuated vaccine during the study.\n9. There are any of the following cardiovascular and cerebrovascular diseases or risk factors for cardiovascular and cerebrovascular diseases:\n\n   Myocardial infarction, unstable angina pectoris, pulmonary embolism, acute\u002Fpersistent myocardial ischemia, cerebrovascular accident, transient ischemic attack, or other arteriovenous thrombosis, embolism, or ischemic events that are clinically significant or require pharmacological intervention occurred within 6 months prior to initial administration.\n\n   Symptomatic congestive heart failure (classified as 3 or 4 according to the New York Heart Association functional classification) occurring within 6 months before the first administration.\n\n   Unstable arrhythmias or degree II\u002FIII atrioventricular blocks requiring pharmacological intervention occurred within 6 months prior to initial administration.\n10. Known history of serious hypersensitivity reaction to other monoclonal antibodies.\n11. Pregnant or lactating women.\n12. Any condition that the investigator believes may result in a risk of receiving the study drug or combination therapy, or that would interfere with the evaluation of the study drug or with patient safety or analysis of the study results.","90 Years",{"count":126,"type":20},670,"This real-world study included all patients with recurrent or metastatic cervical cancer who used Cadonilimab in clinical practice, regardless of treatment lines and combination with different treatments. Through follow-up observations, the aim of this study is to analyze the efficacy of Cadonilimab for recurrent or metastatic cervical cancer in the real world, and to explore the differences in the efficacy of Cadonilimab in different stages of treatment, as well as the efficacy of different treatment combinations, so as to provide clinical evidence for the use of Cadonilimab for recurrent or metastatic cervical cancer.",[25],"2023-11-23",{"date":131,"type":33},"2023-12-04",{"date":133,"type":20},"2023-11-30",{"date":135,"type":20},"2027-11-30",{"name":137,"class":40},"Gang Chen (101199)"]